These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

548 related items for PubMed ID: 26381735

  • 1. Genomic profiling of a Hepatocyte growth factor-dependent signature for MET-targeted therapy in glioblastoma.
    Johnson J, Ascierto ML, Mittal S, Newsome D, Kang L, Briggs M, Tanner K, Marincola FM, Berens ME, Vande Woude GF, Xie Q.
    J Transl Med; 2015 Sep 17; 13():306. PubMed ID: 26381735
    [Abstract] [Full Text] [Related]

  • 2. Combining onartuzumab with erlotinib inhibits growth of non-small cell lung cancer with activating EGFR mutations and HGF overexpression.
    Sano Y, Hashimoto E, Nakatani N, Abe M, Satoh Y, Sakata K, Fujii T, Fujimoto-Ouchi K, Sugimoto M, Nagahashi S, Aoki M, Motegi H, Sasaki E, Yatabe Y.
    Mol Cancer Ther; 2015 Feb 17; 14(2):533-41. PubMed ID: 25522765
    [Abstract] [Full Text] [Related]

  • 3. Crizotinib and erlotinib inhibits growth of c-Met+/EGFRvIII+ primary human glioblastoma xenografts.
    Goodwin CR, Rath P, Oyinlade O, Lopez H, Mughal S, Xia S, Li Y, Kaur H, Zhou X, Ahmed AK, Ho S, Olivi A, Lal B.
    Clin Neurol Neurosurg; 2018 Aug 17; 171():26-33. PubMed ID: 29803091
    [Abstract] [Full Text] [Related]

  • 4. EGFRvIII and c-Met pathway inhibitors synergize against PTEN-null/EGFRvIII+ glioblastoma xenografts.
    Lal B, Goodwin CR, Sang Y, Foss CA, Cornet K, Muzamil S, Pomper MG, Kim J, Laterra J.
    Mol Cancer Ther; 2009 Jul 17; 8(7):1751-60. PubMed ID: 19584231
    [Abstract] [Full Text] [Related]

  • 5. MET Gene Amplification and MET Receptor Activation Are Not Sufficient to Predict Efficacy of Combined MET and EGFR Inhibitors in EGFR TKI-Resistant NSCLC Cells.
    Presutti D, Santini S, Cardinali B, Papoff G, Lalli C, Samperna S, Fustaino V, Giannini G, Ruberti G.
    PLoS One; 2015 Jul 17; 10(11):e0143333. PubMed ID: 26580964
    [Abstract] [Full Text] [Related]

  • 6. Reversion of human glioblastoma malignancy by U1 small nuclear RNA/ribozyme targeting of scatter factor/hepatocyte growth factor and c-met expression.
    Abounader R, Ranganathan S, Lal B, Fielding K, Book A, Dietz H, Burger P, Laterra J.
    J Natl Cancer Inst; 1999 Sep 15; 91(18):1548-56. PubMed ID: 10491431
    [Abstract] [Full Text] [Related]

  • 7. Differential responses of MET activations to MET kinase inhibitor and neutralizing antibody.
    Kou J, Musich PR, Staal B, Kang L, Qin Y, Yao ZQ, Zhang B, Wu W, Tam A, Huang A, Hao HX, Vande Woude GF, Xie Q.
    J Transl Med; 2018 Sep 12; 16(1):253. PubMed ID: 30208970
    [Abstract] [Full Text] [Related]

  • 8. Dual inhibition of Met kinase and angiogenesis to overcome HGF-induced EGFR-TKI resistance in EGFR mutant lung cancer.
    Takeuchi S, Wang W, Li Q, Yamada T, Kita K, Donev IS, Nakamura T, Matsumoto K, Shimizu E, Nishioka Y, Sone S, Nakagawa T, Uenaka T, Yano S.
    Am J Pathol; 2012 Sep 12; 181(3):1034-43. PubMed ID: 22789825
    [Abstract] [Full Text] [Related]

  • 9. Targeting of EGFR increase anti-cancer effects of arsenic trioxide: Promising treatment for glioblastoma multiform.
    Mesbahi Y, Zekri A, Ahmadian S, Alimoghaddam K, Ghavamzadeh A, Ghaffari SH.
    Eur J Pharmacol; 2018 Feb 05; 820():274-285. PubMed ID: 29274334
    [Abstract] [Full Text] [Related]

  • 10. Hepatocyte growth factor (HGF) autocrine activation predicts sensitivity to MET inhibition in glioblastoma.
    Xie Q, Bradley R, Kang L, Koeman J, Ascierto ML, Worschech A, De Giorgi V, Wang E, Kefene L, Su Y, Essenburg C, Kaufman DW, DeKoning T, Enter MA, O'Rourke TJ, Marincola FM, Vande Woude GF.
    Proc Natl Acad Sci U S A; 2012 Jan 10; 109(2):570-5. PubMed ID: 22203985
    [Abstract] [Full Text] [Related]

  • 11. Hepatocyte growth factor sensitizes brain tumors to c-MET kinase inhibition.
    Zhang Y, Farenholtz KE, Yang Y, Guessous F, Dipierro CG, Calvert VS, Deng J, Schiff D, Xin W, Lee JK, Purow B, Christensen J, Petricoin E, Abounader R.
    Clin Cancer Res; 2013 Mar 15; 19(6):1433-44. PubMed ID: 23386689
    [Abstract] [Full Text] [Related]

  • 12. Hyaluronic acid-functionalized gelatin hydrogels reveal extracellular matrix signals temper the efficacy of erlotinib against patient-derived glioblastoma specimens.
    Pedron S, Wolter GL, Chen JE, Laken SE, Sarkaria JN, Harley BAC.
    Biomaterials; 2019 Oct 15; 219():119371. PubMed ID: 31352310
    [Abstract] [Full Text] [Related]

  • 13. Novel MET/TIE2/VEGFR2 inhibitor altiratinib inhibits tumor growth and invasiveness in bevacizumab-resistant glioblastoma mouse models.
    Piao Y, Park SY, Henry V, Smith BD, Tiao N, Flynn DL, de Groot JF.
    Neuro Oncol; 2016 Sep 15; 18(9):1230-41. PubMed ID: 26965451
    [Abstract] [Full Text] [Related]

  • 14. Hepatocyte growth factor expression in EGFR mutant lung cancer with intrinsic and acquired resistance to tyrosine kinase inhibitors in a Japanese cohort.
    Yano S, Yamada T, Takeuchi S, Tachibana K, Minami Y, Yatabe Y, Mitsudomi T, Tanaka H, Kimura T, Kudoh S, Nokihara H, Ohe Y, Yokota J, Uramoto H, Yasumoto K, Kiura K, Higashiyama M, Oda M, Saito H, Yoshida J, Kondoh K, Noguchi M.
    J Thorac Oncol; 2011 Dec 15; 6(12):2011-7. PubMed ID: 22052230
    [Abstract] [Full Text] [Related]

  • 15. Increased HGF Expression Induces Resistance to c-MET Tyrosine Kinase Inhibitors in Gastric Cancer.
    Ahn SY, Kim J, Kim MA, Choi J, Kim WH.
    Anticancer Res; 2017 Mar 15; 37(3):1127-1138. PubMed ID: 28314274
    [Abstract] [Full Text] [Related]

  • 16. Effects of epidermal growth factor receptor and phosphatase and tensin homologue gene expression on the inhibition of U87MG glioblastoma cell proliferation induced by protein kinase inhibitors.
    Xing WJ, Zou Y, Han QL, Dong YC, Deng ZL, Lv XH, Jiang T, Ren H.
    Clin Exp Pharmacol Physiol; 2013 Jan 15; 40(1):13-21. PubMed ID: 23110505
    [Abstract] [Full Text] [Related]

  • 17. Histone Deacetylase Inhibitors Resensitize EGFR/EGFRvIII-Overexpressing, Erlotinib-Resistant Glioblastoma Cells to Tyrosine Kinase Inhibition.
    Liffers K, Kolbe K, Westphal M, Lamszus K, Schulte A.
    Target Oncol; 2016 Feb 15; 11(1):29-40. PubMed ID: 26032687
    [Abstract] [Full Text] [Related]

  • 18. Fully human monoclonal antibodies to hepatocyte growth factor with therapeutic potential against hepatocyte growth factor/c-Met-dependent human tumors.
    Burgess T, Coxon A, Meyer S, Sun J, Rex K, Tsuruda T, Chen Q, Ho SY, Li L, Kaufman S, McDorman K, Cattley RC, Sun J, Elliott G, Zhang K, Feng X, Jia XC, Green L, Radinsky R, Kendall R.
    Cancer Res; 2006 Feb 01; 66(3):1721-9. PubMed ID: 16452232
    [Abstract] [Full Text] [Related]

  • 19. Fibroblast-secreted hepatocyte growth factor mediates epidermal growth factor receptor tyrosine kinase inhibitor resistance in triple-negative breast cancers through paracrine activation of Met.
    Mueller KL, Madden JM, Zoratti GL, Kuperwasser C, List K, Boerner JL.
    Breast Cancer Res; 2012 Jul 12; 14(4):R104. PubMed ID: 22788954
    [Abstract] [Full Text] [Related]

  • 20. Translation of circHGF RNA encodes an HGF protein variant promoting glioblastoma growth through stimulation of c-MET.
    Saunders JT, Kumar S, Benavides-Serrato A, Holmes B, Benavides KE, Bashir MT, Nishimura RN, Gera J.
    J Neurooncol; 2023 May 12; 163(1):207-218. PubMed ID: 37162666
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 28.